|
Berita Reaksi 2017 - Edisi 6/2017
- Ketamine: Risk of Severe Liver Damage with Repeated and/or Prolonged Use at High Doses
- Recombinant Human Erythropoietins: Risk of Severe Cutaneous Adverse Reactions (SCARs)
|
|
Berita Reaksi 2017 - Edisi 5/2017
- Vemurafenib: Risk of Dupuytren’s Contracture and Plantar Fascial Fibromatosis
- Leflunomide and Teriflunomide: Risk of Falsely Decreased Ionised Calcium Levels and Risk of Colitis
|
|
Berita Reaksi 2017 - Edisi 4/2017
- Hyoscine Butylbromide Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease
- Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)
|
|
Berita Reaksi 2017 - Edisi 3/2017
- Loperamide: Risk of Serious Cardiac Adverse Events with High Doses, Including Through Misuse
- Thalidomide, Lenalidomide and Pomalidomide: Risk of Hepatitis B Reactivation, Herpes Zoster and Pulmonary Hypertension
|
|
REAKSI March 2017
- Interferon alfa & Interferon beta: Risk of Pulmonary Arterial Hypertension
- Fluconazole: Caution in Use During Pregnancy
|
|
REAKSI Januari 2017
- Eylea ® vs. Zaltrap ® (aflibercept):Same Active Ingredient,Different Safety Profiles?
|
|
REAKSI November 2016
- Infliximab: Risk of Cervical Cancer
- Implanon NXT® (etonogestrel implant): Reports of Implants Found in the Vasculature and Lung
|
|
REAKSI September 2016
- Live Attenuated Vaccines: Reminder to Avoid Use In Immunosuppressed Individuals
|
|
REAKSI Julai 2016
- Concomitant Use of Spironolactone and Renin-Angiotensin System Drugs in Heart Failure: Risk of Potentially Fatal Hyperkalaemia
- Noxafil® (posaconazole): Tablet and Oral Suspension Not Interchangeable
|
|
REAKSI Mei 2016
- Apomorphine with Domperidone: Minimising the Risk of Cardiac Side Effects
- Locabiotal® Solution (fusafungine): Withdrawal of Registration and Product Recall
|
|
REAKSI Mac 2016
- Proton Pump Inhibitors (PPIs): Potential Long-term Safety Issues
- Paliperidone Palmitate (Invega Sustenna®): Alert on Potential Serious Adverse Events
|
|
REAKSI Januari 2016
- Epoetin-associated Pure Red Cell Aplasia (PRCA): Current Scenario in Malaysia
|
|
REAKSI November 2015
- Testosterone Products: Possible Increased Risk of Heart Attack and Stroke
- Ivabradine: Risk of Cardiovascular Adverse Events
|
|
REAKSI September 2015
- Hydroxyzine: Risk of Effects on Heart Rhythm
- Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Possible Risk of Diabetic Ketoacidosis
|
|
REAKSI Julai 2015
- Patent Ductus Arteriosus (PDA) Closure: Indomethacin vs. Ibuprofen – An Overview of the Local Drug Safety Profiles
|
|
REAKSI Mei 2015
- Bromocriptine: Not to be used routinely for lactation suppression
- Febuxostat: International Reports of Agranulocytosis and DRESS
|
|
REAKSI Mac 2015
- New Alerts on Serious Skin Reactions
- Chlorhexidine Solutions: Risk of Chemical Burns to Skin in Premature Infants
|
|
REAKSI Januari 2015
- Revatio® (sildenafil): Safety Information on Paediatric Use for Pulmonary Arterial Hypertension
|
|
REAKSI November 2014
- Zofran® (ondansetron), Kytril® (granisetron) and Aloxi® (palonosetron): 5-HT3 Receptor Antagonist-associated Serotonin Syndrome
|
|
REAKSI September 2014
- Methylphenidate: Risk of Priapism
- Filgrastim and Pegfilgrastim: Risk of Capillary Leak Syndrome
|
|
REAKSI Julai 2014
- Risperidone and Paliperidone: Risk of Intraoperative Floppy Iris Syndrome
- Temozolomide: Risk of Hepatotoxicity
- MencevaxACWY® Vaccine: New Data on Antibody Persistence
|
|
REAKSI Mei 2014
- Sodium Phosphate Oral Solutions and Enemas: Possible Harm Associated With Overdose
|
|
REAKSI Mac 2014
- Pure Red Cell Aplasia (PRCA) related to use of Erythropoietin Stimulating Agents
|
|
REAKSI Januari 2014
- Comparison and updates on New Oral Anticoagulants (NOACs):
- Dabigatran etexilate (Pradaxa®)
- Rivaroxaban (Xarelto®)
- Apixaban (Eliquis®)
|
|
REAKSI November 2013
- Tygacil® (tigecycline): Reminder on the Increased Risk of Death
- Lariam® (mefloquine): Visual Disturbances Including Optic Neuropathy
|
|
Reaksi September 2013
- Montelukast: Reminder on the Neuropsychiatric Risks
- Roflumilast: Risk of Suicidal Behaviour
|
|
Reaksi Julai 2013
- Sodium Valproate: Risk of Decreased IQ Scores in Children After Fetal Exposure
- Codeine Use in Children: Rare but Life-threatening Adverse Events or Death after Tonsillectomy and/or Adenoidectomy
|
|
Reaksi Mei 2013
- Zithromax/ Zmax (azithromycin): Risk of potentially fatal irregular heart rhythms
- Botulinum Toxin Products: Rare but serious risk of distant toxin spread and non-interchangeability of products
|
|
Reaksi Mac 2013
- Prolia and Xgeva (denosumab): Associated with risk of anaphylactic reactions and atypical femoral fracture
- Invirase (saquinavir): Removal of paediatric dosing recommendation due to potential for QT and PR interval prolongation
|
|
Reaksi Januari 2013
- Pradaxa (dabigatran): New Contraindication in patients with prosthetic heart valve replacement
- MabThera (rituximab)- associated Toxic Epidermal Necrolysis and Stevens-Johnson Syndrome
- Tredaptive/ Pelzont/ Trevaclyn (nicotinic acid/ laropiprant): Suspension of dyslipidaemia drug in the European Union
|
|
Reaksi November 2012
- Pradaxa® (dabigatran etexilate): Not Recommended in Patients with Prosthetic Heart Valves
- Gilenya® (fingolimod hydrochloride): Risk of Cardiovascular Events
- Victrelis® (boceprevir): Drug Interactions With Ritonavir-boosted HIV Protease Inhibitors
|
|
Reaksi September 2012
- Volibris® (ambrisentan): Contraindication in Patients with Idiopathic Pulmonary Fibrosis (IPF)
- Prolia® (denosumab): Risk of Atypical Femoral Fracture
- Case Report: Zometa® (zoledronic acid) Associated Osteomyelitis
|
|
Reaksi Julai 2012
- Velcade® (Bortezomib): Fatal Cases Due To Erroneous Intrathecal Administration
- Bondronat® (Ibandronic Acid): Association With Anaphylactic Reaction
- Case Report: Amiodarone Associated Thyroid Dysfunction
|
|
Reaksi Mei 2012
- Finasteride:
- Sexual Dysfunction that Continued After Treatment Discontinuation
- Suspected ADR on Sexual Dysfunction: 2 case reports
- Potential Rare Risk of Breast Cancer in Men
|
|
Reaksi Mac 2012
- Clostridium difficile - Associated Diarrhoea (CDAD) may be linked to Proton Pump Inhibitors (PPIs)
- Association of Domperidone Maleate with Serious Ventricular Arrhythmia and Sudden Cardiac Death
- Malathion: 2 ADR case reports
|
|
Reaksi Januari 2012
- Avastin® (bevacizumab): Severe Infectious Endophthalmitis Leading to Blindness Following Unapproved Intravitreal Injection
- Saphris® (asenapine maleate): Potential Risk of Serious Allergic Reactions
- Xigris® [drotrecogin alfa (activated)]: Voluntary Market Withdrawal due to Failure to Show Survival Benefit
|
|
Reaksi September 2011
- Ketoconazole: Suspension of Marketing Authorisation in France Due to Risk of Severe Hepatotoxicity
- Champix® (Varenicline): Potential Risk of Certain Cardiovascular Events In Patients with Cardiovascular Disease
- Zyvox (Linezolid) & Methylene Blue: Serious Central Nervous System Reactions Possible When Given to Patients Taking Certain Psychiatric Medications
|
|
Reaksi Julai 2011
- Drospirenone-containing oral contraceptives (OC): Possible increased risk of venous thromboembolism
- Pioglitazone: Suspension in France due to increased risk of bladder cancer
- Rituximab: Fatal infusion-related reactions in rheumatoid arthritis
|
